Latest Competition News

S2 Resources has identified significant gold-arsenic and gold-antimony soil anomalies at its Silver Spoon project in Victoria, signalling promising exploration potential near major regional mines.

Aldoro Resources has finalised the sale of its Wyemandoo Project to Coppermoly, receiving A$100,000 and redirecting its efforts towards its flagship Kameelburg project.

EVE Health Group has announced a $1.3 million capital raising through a placement of shares and free attaching options, aimed at advancing its pharmaceutical product rollout and development pipeline. Several components of the offer await shareholder approval at an upcoming general meeting.

The Australian Government has increased financial support thresholds for Viva Energy’s Geelong Refinery, reflecting rising operating costs and reinforcing domestic fuel security through the decade.

AdAlta Limited has been granted a key Canadian patent for its anti-fibrotic drug AD-214, completing its composition of matter protection across all major commercial markets. This milestone strengthens the company’s intellectual property portfolio and underpins its commercial strategy for AD-214.

WCM Global Growth Limited has successfully completed a significant capital raising, issuing nearly 48.5 million new shares and securing $84.8 million through entitlement, shortfall offers, and a placement.

Klevo Rewards’ subsidiary Fly Wallet has gained multi-jurisdictional certification, paving the way for its corporate card programs across 18 international markets.

Advanced Energy Minerals is ramping up production capacity at its Quebec plant, leveraging patented low-cost technology and renewable energy to meet booming global demand for high purity alumina.

Atlas Arteria has announced an ordinary dividend of AUD 0.20 per security for the six months ending December 2025, payable in April 2026. The dividend is fully unfranked, reflecting foreign income components.

SunRice Group maintains its forecast for profit growth in FY26, even as revenue is expected to remain flat or slightly decline due to competitive pressures, adverse weather, and geopolitical disruptions.

Recce Pharmaceuticals is progressing its Phase 3 clinical trial of RECCE 327, a novel synthetic antibiotic targeting multidrug-resistant infections, with interim data from Indonesia supporting registration plans across ASEAN by 2026.

Finder Energy has confirmed the technical feasibility of repurposing the Petrojarl I FPSO vessel for its Kuda Tasi and Jahal oil fields, setting the stage for a final investment decision by mid-2026.